BeOne Medicines (BEIGF) Change in Accured Expenses (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Change in Accured Expenses data on file, last reported at $1.7 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $1.7 million, up 103.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.1 million (up 503.24% YoY), and the FY2025 annual result was $19.0 million, up 227.83% from the prior year.
• Change in Accured Expenses slipped to $1.7 million in Q1 2026 per BEIGF's latest filing, from $15.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $128.0 million in Q2 2025 and troughed at -$79.3 million in Q1 2024.
• A 5-year average of $3.1 million and a median of $197000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 3364.56% in 2022, then slumped 40358.38% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $44.0 million in 2022, then slumped by 212.51% to -$49.5 million in 2023, then jumped by 70.28% to -$14.7 million in 2024, then soared by 204.81% to $15.4 million in 2025, then plunged by 88.77% to $1.7 million in 2026.
• Business Quant data shows BEIGF's Change in Accured Expenses at $1.7 million in Q1 2026, $15.4 million in Q4 2025, and -$72.1 million in Q3 2025.